Status:
COMPLETED
Refractive Error and Biometry in Retinopathy of Prematurity
Lead Sponsor:
San Ni Chen
Conditions:
Retinopathy of Prematurity
Eligibility:
All Genders
3-3 years
Brief Summary
The investigators compared long-term refractive and biometric outcomes in children with retinopathy of prematurity who received two different anti-vascular endothelial growth factor agents.
Detailed Description
Purpose: To compare refractive and biometric outcomes in patients with type 1 retinopathy of prematurity (ROP) treated with intravitreal injection of Ranibizumab (IVR), versus bevacizumab (IVB), at a...
Eligibility Criteria
Inclusion
- children with type 1 retinopathy of prematurity
- children received anti-vascular endothelial growth factors (bevacizumab or ranibizumab)
Exclusion
- children withour retinopathy of prematurity
- children with retinopathy of prematurity received laser therapy
Key Trial Info
Start Date :
April 1 2011
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 1 2014
Estimated Enrollment :
35 Patients enrolled
Trial Details
Trial ID
NCT03334513
Start Date
April 1 2011
End Date
April 1 2014
Last Update
November 7 2017
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.